UNSPSC 51311611: Setastine hydrochloride

This classification denotes a histamine-1 receptor antagonist C22H28ClNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2MB6P84ON, chemically known as setastine hydrochloride, (+/-)-, but more generally known as setastine hydrochloride, which bears US NIH Compound Identifier 43081. European Medicines Agency schedules Setastine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15235MIG.

Most nations, for tariff and trade purposes, schedule setastine hydrochloride under HS 29339930 and SITC 51577. As of Q4 2014, SETASTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCCCC1)(C2CCC(CC2)CL)OCCN3CCCCCC3.CL.

UNSPSC 51311611 Setastine hydrochloride is a Commodity code. The recent state and local opportunities tagged under this code do not represent setastine hydrochloride procurement; instead, they reflect broad pharmaceutical supply sourcing—naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State and local buyers under this code family are acquiring pharmaceutical products through competitive bidding and cooperative purchasing vehicles to support county health departments, state pharmacy benefit programs, and multi-jurisdictional health systems. The actual procurement activity spans naloxone for opioid response, generic pharmaceuticals and OTC products distributed through authorized wholesalers, and exploratory direct-contracting models for prescription fulfillment. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple states and local governments.

Recent opportunities show activity across Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, gathering vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must demonstrate cGMP compliance, Drug Supply Chain Security Act certification, and pricing flexibility; MMCAP evaluates on price competitiveness (75 percent) and administrative compliance (25 percent combined).